- Home
- Companies
- SOPHiA Genetics
- software
- SOPHiA DDM - Comprehensive Genomic ...
SOPHiA DDM -Comprehensive Genomic Profiling (CGP)
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next generation sequencing (NGS) applications that help maximize insights from CGP data by leveraging advanced analytical capabilities, intutive interpretation features, and one-click reporting.
- Uncover data insights from multi-cancer biomarkers and genetic mutations.
- Retain ownership of your samples and data by bringing CGP workflows in-house.
- Save time and precious sample material by consolidating testing.
- Gain access to a fast and worry-free transition to routine analysis in your laboratory.
OncoPortal™ Plus matches tumor molecular profiles with clinical associations and available clinical trials, leveraging expertly curated evidence powered by JAX-CKB™.
After interpretation, the flexible reporting tools enable users to prepare one-click, comprehensive reports that save time and are customizable to your needs.
The SOPHiA DDM™ Platform offers in-house workflows that are expertly designed to facilitate the analysis and interpretation of relevant variants and biomarkers from DNA and RNA. With both bundle and dry lab applications available, we provide CGP options that suit your lab’s unique set-up and requirements.
Adoption of our genomic applications is made easy with the SOPHiA DDM™ MaxCare Program, empowering teams to gain confidence in their results, establish workflow efficiency, meet quality standards, and ensure performance by offering comprehensive training and analytical performance assessment.
Interested in complementing your CGP workflow with liquid biopsy analysis? Advance your oncology research to new horizons with SOPHiA DDM™ for Liquid Biopsy.
To facilitate variant annotation and interpretation, CGP is increasingly being included in guidelines and recommendations1,2. Our CGP applications are designed to cover genes of emerging and known associations to multiple tumor types, ensuring that you stay ahead of the changing guidelines landscape in your cancer research.
The SOPHiA DDM™ Platform uses proprietary algorithms to efficiently call, annotate, and pre-classify variants and biomarkers, including single nucleotide variants (SNVs), copy number variations (CNVs), insertions and deletions (Indels), gene fusions, microsatellite instability (MSI), genomic integrity and tumor mutational burden (TMB) from raw NGS data.
Our CGP applications supports accurate variant calling and biomarker detection in key genes associated with solid tumors, allowing you to pinpoint the most relevant alterations for your lab.
Mustard™ technology demonstrated analytically accurate MSI detection in colorectal and endometrial cancer (100%), as well as in more challenging tumor types such as glioma (97.8%)3.
TMB measurement
SOPHiA DDM™ demonstrated high correlation of overall (R2 = 0.99) and non-synonymous (R2 = 0.99) TMB estimation when compared to established reference method4.
Based on concordance with TSO500 LocalApp v2.2 comparing Mut/Mb in 64 samples, including 53 clinical FFPE tissue samples from more than 10 tumor types.
Novel fusion detection
SOPHiA DDM™ RNAtarget Technology demonstrated high analytical sensitivity (100%) and specificity (99.99%) for novel (partner-agnostic) fusion detection in RNA and tNA samples5.
